Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 325, Issue 3, pp 226–233 | Cite as

Ra Adenosine receptors in human platelets

Characterization by 5′-N-ethylcarboxamido [3H]adenosine binding in relation to adenylate cyclase activity
  • E. Hüttemann
  • D. Ukena
  • V. Lenschow
  • U. Schwabe


Adenosine receptors in human platelet membranes have been characterized by radioligand binding and measurement of adenylate cyclase activity. Binding of 5′-N-ethylcarboxamido[3H]adenosine ([3H]NECA) was rapid, reversible and dependent on protein concentration, pH and temperature. Due to a rapid rate of dissociation (t1/2 approximately 20 s) binding was highest at 0° C. Adenosine deaminase and GTP alone did not influence [3H]NECA binding, whereas several divalent cations decreased binding. Saturation experiments revealed two different binding sites for [3H]NECA, with Kd values of 0.16 and 2.9 μmol/l and Bmax values of 8.4 and 33.4 pmol/mg of protein. In competition experiments NECA was the most potent adenosine agonist (IC50 0.5 μmol/l), followed by 2-chloroadenosine (IC50 6.3 μmol/l) and adenosine (IC50 12μmol/l). A similar rank order of potencies was observed for the stimulatory effect of adenosine analogues on platelet adenylate cyclase. NECA stimulated adenylate cyclase activity with an EC50 value of 0.5 μmol/l and was approximately 4-fold more potent than (−)N6-phenylisopropyladenosine [(−)PIA]. However, (−)PIA and N6-cyclohexyladenosine did not significantly affect [3H]NECA binding, an observation not consistent with the stimulatory effect on adenylate cyclase. The adenosine antagonists 3-isobutyl-1-methylxanthine, theophylline and caffeine showed IC50 values between 98 and 5,600 μmol/l. [3H]PIA bound to platelet membranes with very low affinity and was not displaced by NECA. The [3H]NECA binding to human platelet membranes satisfies essential criteria for Ra adenosine receptors and, with some limitations, should be of value for the characterization of adenosine receptors in Ra subtype selective cells.

Key words

Adenosine receptors Methylxanthines Adenylate cyclase Platelets Adenosine analogues 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bruns RF (1980) Adenosine receptor activation in human fibroblasts: Nucleoside agonists and antagonists. Can J Physiol Pharmacol 58:673–691Google Scholar
  2. Bruns RF, Daly JW, Snyder SH (1980) Adenosine receptors in brain membranes: Binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8-[3H]phenylxanthine. Proc Natl Acad Sci USA 77:5547–5551Google Scholar
  3. Cusack NJ, Hourani SMO (1981) 5′-N-Ethylcarboxamidoadenosine: A potent inhibitor of human platelet aggregation. Brit J Pharmacol 72:443–447Google Scholar
  4. Daly JW (1982) Adenosine receptors: Targets for future drugs. J Med Chem 25:197–207Google Scholar
  5. Dietmann K, Birkenheier H, Schaumann W (1970) Hemmung der induzierten Thrombocyten-Aggregation druch Adenosin und Adenosin-Derivate. II. Korrelation zwischen Hemmung der Aggregation und peripherer Vasodilatation. Arzneimittelforsch 20:1749–1751Google Scholar
  6. Goodman RR, Cooper MJ, Gavish M, Snyder SH (1982) Guanine nucleotide and cation regulation of the binding of [3H]cyclohexyladenosine and [3H]diethylphenylxanthine to adenosine A1 receptors in brain membranes. Mol Pharmacol 21:329–335Google Scholar
  7. Haslam RJ, Cusack NJ (1981) Blood platelet receptors for ADP and for adenosine. In: Burnstock G (ed) Purinergic receptors. Chapman and Hall, London New York, pp 223–285Google Scholar
  8. Haslam RJ, Rosson GM (1975) Effects of adenosine on levels of adenosine cyclic 3′,5′-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol 11:528–544Google Scholar
  9. Haslam RJ, Davidson MML, Desjardins JV (1978) Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Biochem J 176:83–95Google Scholar
  10. Jakobs KH, Saur W, Schultz G (1976) Reduction of adenylate cyclase activity in lysates of human platelets by the alphaadrenergic component of epinephrine. J Cyclic Nucleotide Res 2:381–392Google Scholar
  11. Jakobs KH, Saur W, Johnson RA (1979) Regulation of platelet adenylate cyclase by adenosine. Biochim Biophys Acta 583: 409–421Google Scholar
  12. Lenschow V, Schwabe U (1982) Effects of guanine nucleotides on adenosine receptors in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 319:R6Google Scholar
  13. Lenschow V, Hüttemann E, Ukena D, Schwabe U (1982) Study of R a adenosine receptors in human platelets by radioligand binding. Naunyn-Schmiedeberg's Arch Pharmacol 321:R39Google Scholar
  14. Londos C, Wolff J (1977) Two distinct adenosine-sensitive sites on adenylate cyclase. Proc Natl Acad Sci USA 12:5482–5486Google Scholar
  15. Londos C, Cooper DMF, Wolff J (1980) Subclasses of external adenosine receptors. Proc Natl Acad Sci USA 77:2551–2554Google Scholar
  16. Londos C, Wolff J, Cooper DMF (1981) Adenosine as a regulator of adenylate cyclase. In: Burnstock G (ed) Purinergic receptors. Chapman and Hall, London New York, pp 289–323Google Scholar
  17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275Google Scholar
  18. Munson PJ, Rodbard D (1980) LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220–239Google Scholar
  19. Schütz W, Tuisl E, Kraupp O (1982a) Adenosine receptor agonists: Binding and adenylate cyclase stimulation in rat liver plasma membranes. Naunyn-Schmiedeberg's Arch Pharmacol 319: 34–39Google Scholar
  20. Schütz W, Steurer G, Tuisl E (1982b) Functional identification of adenylate cyclase-coupled adenosine receptors in rat brain microvessels. Eur J Pharmacol 85:177–184Google Scholar
  21. Schwabe U (1981) Direct binding studies of adenosine receptors. Trends Pharmacol Sci 2:299–303Google Scholar
  22. Schwabe U (1983) General aspects of binding of ligands to adenosine receptors. In: Berne R, Rall TW, Rubio R (eds) The regulatory function of adenosine. Marinus Nijhoff Publishers. The Hague Boston London, pp 77–96Google Scholar
  23. Schwabe U, Trost T (1980) Characterization of adenosine receptors in rat brain by (−)[3H]N6-phenylisopropyladenosine. Naunyn-Schmiedeberg's Arch Pharmacol 313:179–187Google Scholar
  24. Schwabe U, Lenschow V, Ukena D, Ferry DR, Glossmann H (1982) [125I]N6-p-Hydroxyphenylisopropyladenosine, a new ligand for R i adenosine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 321:84–87Google Scholar
  25. Söchtig E, Trost T (1981) Eritadenine: a new tool for investigation of the adenosine P site in plasma membranes of rat fat cells. Pharmacology 23:82–90Google Scholar
  26. Trost T, Schwabe U (1981) Adenosine receptors in fat cells. Identification by (−)-N6-[3H]phenylisopropyladenosine binding. Mol Pharmacol 19:228–235Google Scholar
  27. Tsai BS, Lefkowitz RJ (1979) Agonist-specific effects of guanine nucleotides on alpha-adrenergic receptors in human platelets. Mol Pharmacol 16:61–68Google Scholar
  28. Van Calker D, Müller M, Hamprecht B (1979) Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 33:999–1005Google Scholar
  29. Williams M, Risley EA (1980) Biochemical characterization of putative central purinergic receptors by using 2-chloro-[3H]adenosine, a stable analog of adenosine. Proc Natl Acad Sci USA 77:6892–6896Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • E. Hüttemann
    • 1
  • D. Ukena
    • 1
  • V. Lenschow
    • 1
  • U. Schwabe
    • 1
  1. 1.Institut für Pharmakologie und Toxikologie der Universität BonnBonn 1Federal Republic of Germany

Personalised recommendations